Literature DB >> 11711030

The effects of cyclopentane and cyclopentene analogues of GABA at recombinant GABA(C) receptors.

M Chebib1, R K Duke, R D Allan, G A Johnston.   

Abstract

The pharmacological effects of the enantiomers of cis-3-aminocyclopentanecarboxylic acids ((+)- and (-)-CACP), the enantiomers of trans-3-aminocyclopentanecarboxylic acids ((+)- and (-)-TACP), and the enantiomers of 4-aminocyclopent-1-ene-1-carboxylic acids ((+)- and (-)-4-ACPCA) were studied on human homomeric rho(1) and rho(2) GABA(C) receptors expressed in Xenopus oocytes using two-electrode voltage clamp methods. These compounds are conformationally restricted analogues of gamma-aminobutyric acid (GABA) held in a five-membered ring. (+)-TACP (EC(50) (rho(1))=2.7+/-0.2 microM; EC(50) (rho(2))=1.45+/-0.22 microM), (+)-CACP (EC(50) (rho(1))=26.1+/-1.1 microM; EC(50) (rho(2))=20.1+/-2.1 microM) and (-)-CACP (EC(50) (rho(1))=78.5+/-3.5 microM; EC(50) (rho(2))=63.8+/-23.3 microM) were moderately potent partial agonists at rho(1) and rho(2) GABA(C) receptors, while (-)-TACP (100 microM inhibited 56% and 62% of the current produced by 1 microM GABA at rho(1) and rho(2) receptors, respectively) was a weak partial agonist with low intrinsic activity at these receptors. In contrast, (+)-4-ACPCA (K(i) (rho(1))=6.0+/-0.1 microM; K(i) (rho(2))=4.7+/-0.3 microM) did not activate GABA(C) rho(1) and rho(2) receptors but potently inhibited the action of GABA at these receptors, while (-)-4-ACPCA had little effect as either an agonist or an antagonist. The affinity order at both GABA(C) rho(1) and rho(2) receptors was (+)-TACP>(+)-4-ACPCA >> (+)-CACP>(-)-CACP >> (-)-TACP >> (-)-4-ACPCA. This study shows that the cyclopentane and cyclopentene analogues of GABA affect GABA(C) receptors in a unique manner, defining a preferred stereochemical orientation of the amine and carboxylic acid groups when binding to GABA(C) receptors. This is exemplified by the partial agonist, (+)-TACP, and the antagonist, (+)-4-ACPCA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11711030     DOI: 10.1016/s0014-2999(01)01390-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent γ-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction.

Authors:  Yue Pan; Madina R Gerasimov; Trine Kvist; Petrine Wellendorph; Karsten K Madsen; Elena Pera; Hyunbeom Lee; Arne Schousboe; Mary Chebib; Hans Bräuner-Osborne; Cheryl M Craft; Jonathan D Brodie; Wynne K Schiffer; Stephen L Dewey; Steven R Miller; Richard B Silverman
Journal:  J Med Chem       Date:  2011-12-30       Impact factor: 7.446

Review 2.  GABA-ρ receptors: distinctive functions and molecular pharmacology.

Authors:  Moawiah M Naffaa; Sandy Hung; Mary Chebib; Graham A R Johnston; Jane R Hanrahan
Journal:  Br J Pharmacol       Date:  2017-04-12       Impact factor: 8.739

3.  Novel, potent, and selective GABAC antagonists inhibit myopia development and facilitate learning and memory.

Authors:  Mary Chebib; Tina Hinton; Katrina L Schmid; Darren Brinkworth; Haohua Qian; Susana Matos; Hye-Lim Kim; Heba Abdel-Halim; Rohan J Kumar; Graham A R Johnston; Jane R Hanrahan
Journal:  J Pharmacol Exp Ther       Date:  2008-11-04       Impact factor: 4.030

4.  GABA analogues derived from 4-aminocyclopent-1-enecarboxylic acid.

Authors:  Katherine E S Locock; Graham A R Johnston; Robin D Allan
Journal:  Neurochem Res       Date:  2009-06-02       Impact factor: 3.996

5.  Structurally diverse GABA antagonists interact differently with open and closed conformational states of the ρ1 receptor.

Authors:  Izumi Yamamoto; Jane E Carland; Katherine Locock; Navnath Gavande; Nathan Absalom; Jane R Hanrahan; Robin D Allan; Graham A R Johnston; Mary Chebib
Journal:  ACS Chem Neurosci       Date:  2012-01-13       Impact factor: 4.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.